<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0"><channel><title>Yahoo! Finance: ELN News</title><copyright>Copyright (c) 2009 Yahoo! Inc. All rights reserved.</copyright><link>http://finance.yahoo.com/q/h?s=eln</link><description>Latest Financial News for ELAN CP PLC ADR</description><language>en-us</language><lastBuildDate>Thu, 24 Dec 2009 14:43:06 Etc/GMT</lastBuildDate><image><url>http://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gif</url><title>Yahoo! Finance</title><link>http://finance.yahoo.com</link><width>144</width><height>17</height></image><item><title>This Top Stock Is a Winner (at Motley Fool)</title><link>http://us.rd.yahoo.com/finance/external/mfool/rss/SIG=12i3lk74q/*http%3A//www.fool.com/investing/value/2009/12/24/this-top-stock-is-a-winner.aspx?source=eptyholnk303100&amp;logvisit=y&amp;npu=y</link><description></description><guid isPermaLink="false">yahoo_finance/4170129196</guid><pubDate>Thu, 24 Dec 2009 14:43:06 Etc/GMT</pubDate></item><item><title>This Week&apos;s Failed Trials, Missed Targets in Biotech (at Seeking Alpha)</title><link>http://us.rd.yahoo.com/finance/external/pssa/rss/SIG=12ur4i8sa/*http%3A//seekingalpha.com/article/179030-this-week-s-failed-trials-missed-targets-in-biotech?source=yahoo</link><description></description><guid isPermaLink="false">yahoo_finance/381374615</guid><pubDate>Sun, 20 Dec 2009 12:08:03 Etc/GMT</pubDate></item><item><title>3 Reasons to Buy Dendreon Today (at Motley Fool)</title><link>http://us.rd.yahoo.com/finance/external/mfool/rss/SIG=12t1475gd/*http%3A//www.fool.com/investing/high-growth/2009/12/18/3-reasons-to-buy-dendreon-today.aspx?source=eptyholnk303100&amp;logvisit=y&amp;npu=y</link><description></description><guid isPermaLink="false">yahoo_finance/680562435</guid><pubDate>Fri, 18 Dec 2009 19:34:01 Etc/GMT</pubDate></item><item><title>Another Acquisition for J&amp;J (Zacks.com)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/zacks/091217/28450.html?.v=1</link><description>Johnson &amp; Johnson has been in an acquisitive mode during the year, the Acclarent buyout being the latest.</description><guid isPermaLink="false">yahoo_finance/3986210123</guid><pubDate>Thu, 17 Dec 2009 21:30:58 Etc/GMT</pubDate></item><item><title>Report from Europe: Stocks Recovering After Data Points to Dovish Fed (at Seeking Alpha)</title><link>http://us.rd.yahoo.com/finance/external/pssa/rss/SIG=13fi6e99h/*http%3A//seekingalpha.com/article/178468-report-from-europe-stocks-recovering-after-data-points-to-dovish-fed?source=yahoo</link><description></description><guid isPermaLink="false">yahoo_finance/3022656032</guid><pubDate>Wed, 16 Dec 2009 15:48:29 Etc/GMT</pubDate></item><item><title>Five Biotech Events to Watch in 2010 (at TheStreet.com)</title><link>http://us.rd.yahoo.com/finance/external/tsmfe/rss/SIG=12ub6rpb2/*http%3A//www.thestreet.com/_yahoo/story/10645407/1/five-biotech-events-to-watch-in-2010.html?cm_ven=YAHOO&amp;cm_cat=FREE&amp;cm_ite=NA</link><description></description><guid isPermaLink="false">yahoo_finance/3781450522</guid><pubDate>Wed, 16 Dec 2009 15:23:40 Etc/GMT</pubDate></item><item><title>Five Biotech Events to Watch in 2010 (TheStreet.com)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ts/091216/10645407.html?.v=1</link><description></description><guid isPermaLink="false">yahoo_finance/3756351739</guid><pubDate>Wed, 16 Dec 2009 15:23:40 Etc/GMT</pubDate></item><item><title>Biotech Stocks: Elan, Gilead Sciences lead drug stocks lower (at MarketWatch)</title><link>http://us.rd.yahoo.com/finance/external/cbsm/rss/SIG=12jtl30r6/*http%3A//www.marketwatch.com/news/story/elan-gilead-sciences-lead-drug/story.aspx?guid=%7B5594CA7A%2DCA38%2D4C2A%2DA635%2D145F2DC055FB%7D&amp;siteid=yhoof</link><description>Shares of Elan lose ground over negative reports about its drug candidate for treating Alzheimer&apos;s disease.</description><guid isPermaLink="false">yahoo_finance/4003480282</guid><pubDate>Tue, 15 Dec 2009 20:34:00 Etc/GMT</pubDate></item><item><title>Forget the Higher Doses (at Motley Fool)</title><link>http://us.rd.yahoo.com/finance/external/mfool/rss/SIG=12lk59obq/*http%3A//www.fool.com/investing/high-growth/2009/12/15/forget-the-higher-doses.aspx?source=eptyholnk303100&amp;logvisit=y&amp;npu=y</link><description></description><guid isPermaLink="false">yahoo_finance/1804156387</guid><pubDate>Tue, 15 Dec 2009 20:16:14 Etc/GMT</pubDate></item><item><title>Is This Company Really Earning Money? (at Motley Fool)</title><link>http://us.rd.yahoo.com/finance/external/mfool/rss/SIG=12sfoeiqj/*http%3A//www.fool.com/investing/value/2009/12/15/is-this-company-really-earning-money.aspx?source=eptyholnk303100&amp;logvisit=y&amp;npu=y</link><description></description><guid isPermaLink="false">yahoo_finance/3863879705</guid><pubDate>Tue, 15 Dec 2009 19:10:03 Etc/GMT</pubDate></item><item><title>Elan, Partner to Stop Alzheimers Trial After Nine Deaths (at Fox Business)</title><link>http://us.rd.yahoo.com/finance/external/FoxBusiness.com/rss/SIG=136857p9q/*http%3A//www.foxbusiness.com/story/markets/industries/health-care/elan-stop-alzheimers-trial-deaths/</link><description></description><guid isPermaLink="false">yahoo_finance/58944629</guid><pubDate>Tue, 15 Dec 2009 16:02:21 Etc/GMT</pubDate></item><item><title>Elan partially shuts down Alzheimer drug study (at MarketWatch)</title><link>http://us.rd.yahoo.com/finance/external/cbsm/rss/SIG=12o07vp85/*http%3A//www.marketwatch.com/news/story/elan-partially-shuts-down-alzheimer/story.aspx?guid=%7BCC5B9833%2DF261%2D43EF%2DAAD1%2D65A5928D080D%7D&amp;siteid=yhoof</link><description></description><guid isPermaLink="false">yahoo_finance/1619365773</guid><pubDate>Tue, 15 Dec 2009 15:14:00 Etc/GMT</pubDate></item><item><title>Elan partially shuts down Alzhiemer drug study (at MarketWatch)</title><link>http://us.rd.yahoo.com/finance/external/cbsm/rss/SIG=12o831h8i/*http%3A//www.marketwatch.com/news/story/elan-partially-shuts-down-alzhiemer/story.aspx?guid=%7BCC5B9833%2DF261%2D43EF%2DAAD1%2D65A5928D080D%7D&amp;siteid=yhoof</link><description>Elan Corp. said early Tuesday said that it was discontinuing testing of a higher dose of its Alzheimer&apos;s disease drug candidate after nine deaths were reported in a Phase II clinical study.</description><guid isPermaLink="false">yahoo_finance/152935562</guid><pubDate>Tue, 15 Dec 2009 15:09:00 Etc/GMT</pubDate></item><item><title>RPT-UPDATE - Elan, Transition drop top drug doses after deaths (at Reuters)</title><link>http://us.rd.yahoo.com/finance/external/reuters/rss/SIG=118cks9u6/*http%3A//www.reuters.com/legacyArticle?duid=mtfh85768_2009-12-15_14-43-48_n15222584_newsml&amp;rpc=44&amp;type=marketsNews</link><description></description><guid isPermaLink="false">yahoo_finance/1199039269</guid><pubDate>Tue, 15 Dec 2009 14:43:48 Etc/GMT</pubDate></item><item><title>Elan, Transition modify Alzheimer drug trial (at MarketWatch)</title><link>http://us.rd.yahoo.com/finance/external/cbsm/rss/SIG=11kitjnkn/*http%3A//www.marketwatch.com/News/Story/Story.aspx?guid=%7bBBEF71DA-B98F-47F3-8ADA-6133CD396072%7d&amp;siteid=yhoof2</link><description></description><guid isPermaLink="false">yahoo_finance/1248908307</guid><pubDate>Tue, 15 Dec 2009 13:03:40 Etc/GMT</pubDate></item><item><title>Safety Dogs Elan Alzheimer&apos;s Drug; Seattle Genetics Finds New Partner: BioBuzz (at TheStreet.com)</title><link>http://us.rd.yahoo.com/finance/external/tsmfe/rss/SIG=145rms8u2/*http%3A//www.thestreet.com/_yahoo/story/10645731/1/safety-dogs-elan-alzheimers-drug-seattle-genetics-finds-new-partner-biobuzz.html?cm_ven=YAHOO&amp;cm_cat=FREE&amp;cm_ite=NA</link><description></description><guid isPermaLink="false">yahoo_finance/2408387390</guid><pubDate>Tue, 15 Dec 2009 11:00:50 Etc/GMT</pubDate></item><item><title>Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer&apos;s Disease (Business Wire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091215/20091214006410.html?.v=1</link><description>DUBLIN----Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease.</description><guid isPermaLink="false">yahoo_finance/3482809013</guid><pubDate>Tue, 15 Dec 2009 07:00:00 Etc/GMT</pubDate></item><item><title>This Just In: Upgrades and Downgrades (at Motley Fool)</title><link>http://us.rd.yahoo.com/finance/external/mfool/rss/SIG=132c2camq/*http%3A//www.fool.com/investing/high-growth/2009/12/14/this-just-in-upgrades-and-downgrades.aspx?source=eptyholnk303100&amp;logvisit=y&amp;npu=y</link><description></description><guid isPermaLink="false">yahoo_finance/595656279</guid><pubDate>Mon, 14 Dec 2009 20:03:15 Etc/GMT</pubDate></item><item><title>Finally Released From an Extended Review (at Motley Fool)</title><link>http://us.rd.yahoo.com/finance/external/mfool/rss/SIG=132qdmunl/*http%3A//www.fool.com/investing/general/2009/12/14/finally-released-from-an-extended-review.aspx?source=eptyholnk303100&amp;logvisit=y&amp;npu=y</link><description></description><guid isPermaLink="false">yahoo_finance/3074086678</guid><pubDate>Mon, 14 Dec 2009 19:21:11 Etc/GMT</pubDate></item><item><title>Elan Drug Technologies Announces First Japanese Approval of Product Using Its NanoCrystal® Technology (Business Wire)</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091214/20091213005025.html?.v=1</link><description>DUBLIN----Elan Drug Technologies, a business unit of Elan Corporation, plc announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND® for the treatment of cancer chemotherapy-induced nausea and vomiting.</description><guid isPermaLink="false">yahoo_finance/418437432</guid><pubDate>Mon, 14 Dec 2009 07:00:00 Etc/GMT</pubDate></item></channel></rss><!-- c7.finance.sp2.yahoo.com compressed/chunked Sun Dec 27 10:49:16 PST 2009 -->
